Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6325388 | 0.78 | — | — | |
| SCHEMBL9455389 | 0.76 | — | — | |
| SCHEMBL203037 | 0.76 | — | — | |
| SCHEMBL2776908 | 0.76 | — | — | |
| SCHEMBL1930049 | 0.76 | — | — | |
| SCHEMBL864818 | 0.76 | — | — | |
| Ammonia Solution, Strong SCHEMBL25206010 | 0.73 | TET2 (0.34) | CA2 | |
| SCHEMBL13044838 | 0.73 | — | — | |
| SCHEMBL1635663 | 0.73 | — | — | |
| Potassium Ion SCHEMBL10723738 | 0.73 | CA4 (0.33) | CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 81 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101506185-B | Oxolane is [3,2-B] pyrroles-3-ketone intermediate also | 格兰泰有限公司 | 2016-06-29 | — | — | CN | claimed |
| CN-101506185-A | Tetrahydrofuro [3, 2-B] pyrrol-3-one intermediates | ARMURA THERAPEUTICS LTD (GB) | 2009-08-12 | — | — | CN | claimed |
| EP-2081919-A1 | TETRAHYDROFURO [3, 2-B]PYRR0L-3-0NE INTERMEDIATES | Amura Therapeutics Limited (GB) | 2009-07-29 | — | — | EP | claimed |
| US-20090005575-A1 | Preparation of diazapentalene derivatives via epoxydation of dihydropyrroles | AMURA THERAPEUTICS LTD. (GB) | 2009-01-01 | — | — | US | claimed |
| CN-101273044-A | Preparation of diaza-pentalene derivatives by epoxidation of dihydropyrroles | AMURA THERAPEUTICS LTD (GB) | 2008-09-24 | — | — | CN | claimed |
| EP-1917266-A1 | PREPARATION OF DIAZAPENTALENE DERIVATIVES VIA EPOXYDATION OF DIHYDROPYRROLES | Amura Therapeutics Limited (GB) | 2008-05-07 | — | — | EP | claimed |
| WO-2008007132-A1 | TETRAHYDROFURO [3, 2-B] PYRR0L-3-0NE INTERMEDIATES | AMURA THERAPEUTICS LIMITED (GB) | 2008-01-17 | — | — | WO | claimed |
| WO-2007017698-A1 | PREPARATION OF DIAZAPENTALENE DERIVATIVES VIA EPOXYDATION OF DIHYDROPYRROLES | AMURA THERAPEUTICS LIMITED (GB) | 2007-02-15 | — | — | WO | claimed |
| JP-9067294-A | — | — | None | — | — | JP | disclosed |
| US-20160361295-A1 | FURO[3, 2-B] PYRR0L-3-ONES AS CATHESPIN S INHIBITORS | AMURA THERAPEUTICS LTD (GB) | 2016-12-15 | — | — | US | disclosed |
| CN-101506185-B | Oxolane is [3,2-B] pyrroles-3-ketone intermediate also | 格兰泰有限公司 | 2016-06-29 | — | — | CN | disclosed |
| US-20160015685-A1 | FURO [3, 2-B] PYRR0L-3-0NES AS CATHESPIN S INHIBITORS | AMURA THERAPEUTICS LTD (GB) | 2016-01-21 | — | — | US | disclosed |
| US-20150209349-A1 | Piperazine Compounds | AMURA THERAPEUTICS LTD (GB) | 2015-07-30 | — | — | US | disclosed |
| EP-2240491-B1 | TETRAHYDROFURO(2,3-b)PYRROL-3-ONE DERIVATIVES AS INHIBITORS OF CYSTEINE PROTEINASES | AMURA THERAPEUTICS LTD (GB) | 2015-07-15 | — | — | EP | disclosed |
| WO-2008007132-A1 | TETRAHYDROFURO [3, 2-B] PYRR0L-3-0NE INTERMEDIATES | AMURA THERAPEUTICS LIMITED (GB) | 2008-01-17 | — | — | WO | disclosed |
| WO-2008007127-A1 | FURO [3,2-B] PYRROL-3-ONE DERIVATIVES AND THEIR USE AS CYSTEINYL PROTEINASE INHIBITORS | AMURA THERAPEUTICS LIMITED (GB) | 2008-01-17 | — | — | WO | disclosed |
| WO-2008007114-A1 | TETRAHYDROFURO [3, 2 -B] PYRR0L-3-ONES AS CATHEPSIN K INHIBITORS | AMURA THERAPEUTICS LIMITED (GB) | 2008-01-17 | — | — | WO | disclosed |
| WO-2008007109-A1 | FURO[3,2-B]PYRROL-3-ONE DERIVATIVES AND THEIR USE AS CYSTEINYL PROTEINASE INHIBITORS | AMURA THERAPEUTICS LIMITED (GB) | 2008-01-17 | — | — | WO | disclosed |
| WO-2007017698-A1 | PREPARATION OF DIAZAPENTALENE DERIVATIVES VIA EPOXYDATION OF DIHYDROPYRROLES | AMURA THERAPEUTICS LIMITED (GB) | 2007-02-15 | — | — | WO | disclosed |
| JP-H0967294-A | PRODUCTION OF 5-TRIFLUOROMETHYL-2-CYCLOPENTENONE | NIPPON KASEI CHEM CO LTD | 1997-03-11 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150209349-A1 | Piperazine Compounds | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CHRM1, CHRM5 | CA2 1783/4885 |
| US-20160015685-A1 | FURO [3, 2-B] PYRR0L-3-0NES AS CATHESPIN S INHIBITORS | CTSS, CTSL, CTSK | CA2 288/4885 |
| US-20090005575-A1 | Preparation of diazapentalene derivatives via epoxydation of dihydropyrroles | PTGDR2, PTGER2, PTGDR | CA2 1385/4885 |
| US-20160361295-A1 | FURO[3, 2-B] PYRR0L-3-ONES AS CATHESPIN S INHIBITORS | CTSS, CTSL, CTSK | CA2 210/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.